Onconetix Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenure2.5yrs
Board average tenure1.6yrs

Recent management updates

Recent updates

Here's Why We're Not Too Worried About Blue Water Vaccines' (NASDAQ:BWV) Cash Burn Situation

Jan 24
Here's Why We're Not Too Worried About Blue Water Vaccines' (NASDAQ:BWV) Cash Burn Situation

Blue Water plans to evaluate BWV-201 vaccine for pneumococcal pneumonia

Oct 11

Blue Water Vaccines stock jumps ~22% premarket on plans to develop monkeypox shot

Aug 17

Blue Water Vaccines in pact to study Alzheimer’s vaccine

Jul 20

Blue Water Vaccines: Estimates And Expectations

May 17

CEO

Onconetix has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
James Sapirstein
Executive Chairman3.1yrsUS$182.12k0.042%
$ 445.1
Karina Fedasz
Interim Chief Financial Officerless than a yearno datano data
Andrew Skibo
Global Head of Biologics Operations3.8yrsno datano data
Brian Price
Head of Technology Strategy4.5yrsUS$126.48kno data
Theodore Yoho
Head of Business Development3.8yrsno datano data
Ali Fattom
Head of Science & Discovery2.5yrsno datano data
Jay Newmark
Chief Medical Officer1.9yrsno datano data

2.5yrs

Average Tenure

Experienced Management: ONCO's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
James Sapirstein
Executive Chairman3.1yrsUS$182.12k0.042%
$ 445.1
John Rice
Member of Scientific Advisory Boardno datano datano data
Thomas Meier
Independent Director1.1yrsno data0.040%
$ 424.7
Andrew Oakley
Directorless than a yearno datano data
Ajit Singh
Independent Director1.1yrsno data0.041%
$ 434.7
Sunetra Gupta
Member of Scientific Advisory Boardno datano datano data
Simon Tarsh
Independent Director2.6yrsUS$112.62k0.042%
$ 445.1
Timothy Ramdeen
Independent Non-Executive Director2.2yrsUS$82.67k0.042%
$ 445.1

1.6yrs

Average Tenure

62yo

Average Age

Experienced Board: ONCO's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/23 01:07
End of Day Share Price 2025/03/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Onconetix, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vernon BernardinoH.C. Wainwright & Co.
Jason McCarthyMaxim Group